AZD6738 for Patients With Progressive MDS or CMML

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

August 5, 2019

Primary Completion Date

April 9, 2025

Study Completion Date

May 31, 2026

Conditions
LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

AZD6738

MDS and CMML cells rely specifically on the ATR pathway to fix DNA damage and survive; by inhibiting ATR with AZD6738, MDS or CMML cells appear to selectively accumulate DNA damage and die, but healthy cells appear to be less sensitive to this target

Trial Locations (4)

63110

Washington University, St Louis

02215

BIDMC, Boston

Dana-Farber Cancer Institute, Boston

Massachusetts General Hospital Cancer Center, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Massachusetts General Hospital

OTHER